IASLC > International Association for the Study of Lung Cancer > About IASLC > News Detail

Journal of Thoracic Oncology Impact Factor Continues to Increase

Monday, June 29, 2020

Journal of Thoracic Oncology Impact Factor Continues to Increase
Growth Represents the Quality of Research and the Speed to Publication for the IASLC’s Official Journal

DENVER – The International Association for the Study of Lung Cancer (IASLC) today reported that its main cancer journal, the Journal of Thoracic Oncology, improved its impact score from 12.460 in 2018 to 13.357 in 2019.  The JTO, the official journal of the IASLC, now ranks 11th out of all 244 oncology journals and 3rd out of all 64 respiratory system journals. 

Impact Factors are measured by calculating the number of times journal articles in the two preceding years are cited in a current year. Thus, the impact factor for 2019 is the number of times articles published in 2017 and 2018 are cited in 2019.  The higher the impact factor, the more highly ranked the journal.  Journal citation reports are issued by Clarivate Analytics.

The JTO is the primary educational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Emphasizing a multidisciplinary approach, the JTO includes original research, review articles and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists and basic scientists with a special interest in thoracic oncology.

“With this new impact factor, JTO is now among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology,” said Dr. Alex Adjei, Editor-in-Chief. “Our strong editorial team handles manuscripts quickly, the IASLC supports JTO’s mission and the thoracic oncology clinical and research community’s strong collaboration all contribute to this achievement.”

The JTO continues to have a quick turn-around time of 5.4 days to initial decision, and an average of 7 days for revisions, a fast track category, publish on acceptance (within 5 days) and promotion of select articles via social media and press releases. In 2020, IASLC also launched an open access journal, JTO Clinical and Research Reports, to expand their ability to publish quality research In thoracic oncology. Authors can promote their own research by utilizing Elsevier enhancements such as Sharelink.

To submit a manuscript or to learn more about the JTO, please visit jto.org. Once there, readers can peruse current in-press articles, collections of lung cancer staging and pathology articles and the freely available Editor’s Choice articles. The full contents of the JTO are a free benefit for IASLC members.

About the IASLC: The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the JTO: Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. 


About the Author

Chris Martin, Vice President, Public Relations